Wellington Management Group LLP Lowers Holdings in LivaNova PLC $LIVN

Wellington Management Group LLP lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 8.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,739,167 shares of the company’s stock after selling 151,482 shares during the period. Wellington Management Group LLP’s holdings in LivaNova were worth $143,012,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Hantz Financial Services Inc. lifted its position in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the period. Public Employees Retirement System of Ohio bought a new position in LivaNova in the second quarter worth approximately $37,000. State of Wyoming bought a new position in LivaNova in the second quarter worth approximately $31,000. Quarry LP purchased a new stake in LivaNova during the third quarter worth $36,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LIVN. Freedom Capital upgraded LivaNova to a “hold” rating in a report on Tuesday, June 30th. Stifel Nicolaus set a $85.00 price objective on LivaNova in a research note on Wednesday, August 5th. Barclays raised their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Zacks Research lowered LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, Robert W. Baird reduced their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $83.50.

LivaNova Stock Performance

Shares of LIVN stock opened at $79.81 on Tuesday. The business’s fifty day simple moving average is $80.64 and its 200-day simple moving average is $72.49. The company has a market cap of $4.40 billion, a PE ratio of 23.61 and a beta of 0.86. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. LivaNova PLC has a 12-month low of $48.82 and a 12-month high of $85.76.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The firm had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. During the same quarter last year, the firm earned $1.05 EPS. The business’s quarterly revenue was up 10.8% on a year-over-year basis. Analysts expect that LivaNova PLC will post 3.77 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.